Intellia Therapeutics (NTLA) Equity Income (2021 - 2023)

Intellia Therapeutics (NTLA) has 3 years of Equity Income data on file, last reported at -$4.7 million in Q4 2023.

• Equity Income for Q4 2023 came in at -$4.7 million, down 45.57% year-over-year; the trailing twelve-month figure through Sep 2024 was -$4.7 million (up 66.59% YoY), and the FY2023 annual result was -$15.6 million, down 41.1% from the prior year.
• Equity Income retreated to -$4.7 million in Q4 2023 per NTLA's latest filing, from -$3.9 million in the prior quarter.
• Over five years, Equity Income peaked at -$1.3 million in Q4 2021 and troughed at -$4.7 million in Q4 2023.
• A 3-year average of -$3.1 million and a median of -$3.2 million in 2022 frame the typical range for Equity Income.
• The sharpest annual moves came in 2022 and 2023: Equity Income plunged 145.13% in 2022, then dropped 11.04% in 2023.
• A 3-year view of Equity Income shows it stood at -$1.3 million in 2021, then sank by 145.13% to -$3.2 million in 2022, then sank by 45.57% to -$4.7 million in 2023.
• Business Quant data shows NTLA's Equity Income at -$4.7 million in Q4 2023, -$3.9 million in Q3 2023, and -$4.0 million in Q2 2023.